Literature DB >> 35582173

The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI.

Arash Rashidi1, Chintan Shah2, Miroslav Sekulic3.   

Abstract

AKI in the setting of immune checkpoint inhibitors.Need for kidney biopsy for diagnosis of immune checkpoint inhibitors.Importance of pathology in diagnosis of immune checkpoint inhibitor-induced AKI.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  acute kidney injury; biopsy; clinical nephrology; immune checkpoint inhibitors

Mesh：

Substances：

Year:  2022        PMID： 35582173      PMCID： PMC9034825          DOI： 10.34067/KID.0000232022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


  13 in total

1.  An unknown reaction to pembrolizumab: giant cell arteritis.

Authors:  I Micaily; M Chernoff
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

2.  Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4.

Authors:  Barbara L Goldstein; Lydia Gedmintas; Derrick J Todd
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

3.  Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases.

Authors:  Abhijat Kitchlu; Warren Fingrut; Carmen Avila-Casado; Christopher T Chan; Michael Crump; David Hogg; Heather N Reich
Journal:  Am J Kidney Dis       Date:  2017-06-23       Impact factor: 8.860

4.  Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: CON.

Authors:  Victoria Gutgarts; Ilya G Glezerman
Journal:  Kidney360       Date:  2020-02-11

5.  Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.

Authors:  Anushree C Shirali; Mark A Perazella; Scott Gettinger
Journal:  Am J Kidney Dis       Date:  2016-04-22       Impact factor: 8.860

6.  Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.

Authors:  Frank B Cortazar; Kristen A Marrone; Megan L Troxell; Kenneth M Ralto; Melanie P Hoenig; Julie R Brahmer; Dung T Le; Evan J Lipson; Ilya G Glezerman; Jedd Wolchok; Lynn D Cornell; Paul Feldman; Michael B Stokes; Sarah A Zapata; F Stephen Hodi; Patrick A Ott; Michifumi Yamashita; David E Leaf
Journal:  Kidney Int       Date:  2016-06-07       Impact factor: 10.612

7.  Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report.

Authors:  Robin A Daanen; Rutger J H Maas; Rutger H T Koornstra; Eric J Steenbergen; Carla M L van Herpen; Annelieke E C A B Willemsen
Journal:  J Immunother       Date:  2017 Nov/Dec       Impact factor: 4.456

8.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

Authors:  Bryan J Schneider; Jarushka Naidoo; Bianca D Santomasso; Christina Lacchetti; Sherry Adkins; Milan Anadkat; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marianne J Davies; Marc S Ernstoff; Leslie Fecher; Monalisa Ghosh; Ishmael Jaiyesimi; Jennifer S Mammen; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Cristina A Reichner; Carole Seigel; Jung-Min Song; Alexander Spira; Maria Suarez-Almazor; Umang Swami; John A Thompson; Praveen Vikas; Yinghong Wang; Jeffrey S Weber; Pauline Funchain; Kathryn Bollin
Journal:  J Clin Oncol       Date:  2021-11-01       Impact factor: 44.544

9.  Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.

Authors:  Alejandro Meraz-Muñoz; Eitan Amir; Pamela Ng; Carmen Avila-Casado; Claire Ragobar; Christopher Chan; Joseph Kim; Ron Wald; Abhijat Kitchlu
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751
View more
  2 in total

1.  Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study.

Authors:  Mónica Bolufer; Clara García-Carro; Miquel Blasco; Luis F Quintana; Amir Shabaka; Cristina Rabasco; Juliana Draibe; Ana Merino; María Rosa Melero; Fabiola Alonso; Anna Buxeda; Paula Batalha; Maria Teresa Visús; Maria José Soler
Journal:  J Clin Med       Date:  2022-05-21       Impact factor: 4.964

Review 2.  Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

Authors:  Sheila Bermejo; Mónica Bolufer; Mar Riveiro-Barciela; Maria José Soler
Journal:  Front Med (Lausanne)       Date:  2022-06-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.